Newsroom

April 19, 2023

Read Now Button

2023 Spring Newsletter

Be sure to catch up on the latest happenings in our spring newsletter.

March 27, 2023

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneurophathy (ATTRv-PN) through 66 weeks

Published 27 March 2023

February 2, 2023

Read now button

2023 Winter Newsletter

Be sure to catch up on the latest happenings in our winter newsletter here!

November 30, 2022

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022

November 5, 2022

November 16, 2022

Read Now button

2022 Fall Newsletter

Be sure to catch up on the latest happenings in our fall newsletter.